The prognostic genes of GBM IDH mutant were HSPA5 and NFE2L2; GBM IDH wildtype were ATG7 and MAPK9; A/AA group includes BID, LAMP2 and MAPK3; ATG5, BECN1, GABARAPL1 and HSPA5 were prognostic genes in the O/AO subgroup; In the clinical risk assessment (Figure 8), Type (primary/recurrence), radiotherapy, and TMZ were prognostic factors for GBM IDH wildtype; Type (primary/recurrence) and Grade were prognostic factors for O/AO. This evidence concerns the gene NFE2L2 and glioblastoma.